OBJECTIVE: To describe the effect of an extended-spectrum prophylactic antibiotic regimen on postcesarean endometritis. METHODS: This is a cohort study of trends in postcesarean endometritis using data both from prospective surveillance by the infection control unit and from query of our obstetric computerized database to compare three periods of antibiotic prophylaxis: standard narrow-spectrum with intravenous first- or second-generation cephalosporin (1992-1996), clinical trial of extended-spectrum with addition of intravenous doxycycline and oral azithromycin (1997-1999), and routine use of extended-spectrum with addition of intravenous azithromycin (2001-2006) to standard cephalosporin prophylaxis. RESULTS: A total of 48,913 deliveries at 24 weeks or more of gestation occurred from 1992 to 2006, of which 10,966 (22.4%) were cesarean deliveries. Annual cesarean rates increased from 16% to 27.5%. Trends in the incidence of postcesarean endometritis revealed a biphasic decrease consistent with the phased introduction of extended-spectrum prophylaxis. Incidence (95% confidence interval [CI]) of endometritis by prospective surveillance dropped from 19.9% (95% CI 18.6-21.3%) to 15.4% (95% CI 13.2-17.9%) during the clinical trial period: relative risk (RR) 0.77 (95% CI 0.66-0.91), P=.002; and then to 6.3% (95% CI 5.0-7.9%) during routine use of extended-spectrum prophylaxis: RR 0.41 (95% CI 0.31-0.54), P<.001. Corresponding incidence by database query dropped from 23% (95% CI 21.5-24.4%) to 16% (95% CI 14.4-17.9%): RR 0.69 (95% CI 0.61-0.79), P<.001; and then to 2.1% (95% CI 1.8-2.6%): RR 0.13 (95% CI 0.11-0.16), P<.001. These findings were unchanged after adjusting for potential confounders. CONCLUSION: Extended-spectrum antibiotic prophylaxis involving the addition of azithromycin to standard narrow-spectrum prophylaxis was associated with a significant reduction in postcesarean endometritis. LEVEL OF EVIDENCE: II.
OBJECTIVE: To describe the effect of an extended-spectrum prophylactic antibiotic regimen on postcesarean endometritis. METHODS: This is a cohort study of trends in postcesarean endometritis using data both from prospective surveillance by the infection control unit and from query of our obstetric computerized database to compare three periods of antibiotic prophylaxis: standard narrow-spectrum with intravenous first- or second-generation cephalosporin (1992-1996), clinical trial of extended-spectrum with addition of intravenous doxycycline and oral azithromycin (1997-1999), and routine use of extended-spectrum with addition of intravenous azithromycin (2001-2006) to standard cephalosporin prophylaxis. RESULTS: A total of 48,913 deliveries at 24 weeks or more of gestation occurred from 1992 to 2006, of which 10,966 (22.4%) were cesarean deliveries. Annual cesarean rates increased from 16% to 27.5%. Trends in the incidence of postcesarean endometritis revealed a biphasic decrease consistent with the phased introduction of extended-spectrum prophylaxis. Incidence (95% confidence interval [CI]) of endometritis by prospective surveillance dropped from 19.9% (95% CI 18.6-21.3%) to 15.4% (95% CI 13.2-17.9%) during the clinical trial period: relative risk (RR) 0.77 (95% CI 0.66-0.91), P=.002; and then to 6.3% (95% CI 5.0-7.9%) during routine use of extended-spectrum prophylaxis: RR 0.41 (95% CI 0.31-0.54), P<.001. Corresponding incidence by database query dropped from 23% (95% CI 21.5-24.4%) to 16% (95% CI 14.4-17.9%): RR 0.69 (95% CI 0.61-0.79), P<.001; and then to 2.1% (95% CI 1.8-2.6%): RR 0.13 (95% CI 0.11-0.16), P<.001. These findings were unchanged after adjusting for potential confounders. CONCLUSION: Extended-spectrum antibiotic prophylaxis involving the addition of azithromycin to standard narrow-spectrum prophylaxis was associated with a significant reduction in postcesarean endometritis. LEVEL OF EVIDENCE: II.
Authors: Methodius G Tuuli; Lucy Liu; Ryan E Longman; Anthony O Odibo; George A Macones; Alison G Cahill Journal: Am J Obstet Gynecol Date: 2014-03-18 Impact factor: 8.661
Authors: Amy E Doss; Jennifer D Davidson; Suzanne P Cliver; Luisa A L Wetta; William W Andrews; Alan T N Tita Journal: J Matern Fetal Neonatal Med Date: 2012-05-03
Authors: Lorie M Harper; Meredith Kilgore; Jeff M Szychowski; William W Andrews; Alan T N Tita Journal: Obstet Gynecol Date: 2017-08 Impact factor: 7.661
Authors: R F Lamont; J D Sobel; J P Kusanovic; E Vaisbuch; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero Journal: BJOG Date: 2011-01 Impact factor: 6.531
Authors: Amelia L Sutton; Edward P Acosta; Kajal B Larson; Corenna D Kerstner-Wood; Alan T Tita; Joseph R Biggio Journal: Am J Obstet Gynecol Date: 2015-01-13 Impact factor: 8.661
Authors: Margaret A Olsen; Anne M Butler; Denise M Willers; Gilad A Gross; Preetishma Devkota; Victoria J Fraser Journal: Infect Control Hosp Epidemiol Date: 2010-01 Impact factor: 3.254
Authors: Alan T N Tita; Jeff M Szychowski; Kim Boggess; George Saade; Sherri Longo; Erin Clark; Sean Esplin; Kirsten Cleary; Ron Wapner; Kellett Letson; Michelle Owens; Adi Abramovici; Namasivayam Ambalavanan; Gary Cutter; William Andrews Journal: N Engl J Med Date: 2016-09-29 Impact factor: 91.245
Authors: Alan T N Tita; Dwight J Rouse; Sean Blackwell; George R Saade; Catherine Y Spong; William W Andrews Journal: Obstet Gynecol Date: 2009-03 Impact factor: 7.661